Business Wire

ILiAD and hVIVO Sign LOI for Pivotal Phase 3 Trial of BPZE1 Pertussis Vaccine Following FDA Meeting

WESTON, Fla.--(BUSINESS WIRE)--ILiAD Biotechnologies, LLC, a biotech company developing BPZE1, the most advanced next generation intranasal pertussis vaccine to protect against whooping cough, today ...
Business Wire

ILiAD Biotechnologies Announces $42.8M Financing Round to Advance BPZE1 Pertussis Vaccine

WESTON, Fla.--(BUSINESS WIRE)--ILiAD Biotechnologies, LLC (ILiAD), a clinical stage biotech company developing the world’s most advanced next generation pertussis vaccine, today announced the closing ...
Morningstar

ILiAD Biotechnologies Announces Lancet Microbe Publication of BPZE1 Phase 2b Clinical Results in Human Challenge Model

ILiAD Biotechnologies, LLC (ILiAD), an advanced clinical stage biotech company focused on the prevention and treatment of disease caused by Bordetella Pertussis, today announced the peer-reviewed ...
National Academies of Sciences%2c Engineering%2c and Medicine

Adverse Effects of Pertussis and Rubella Vaccines

Unfortunately, this book can't be printed from the OpenBook. If you need to print pages from this book, we recommend downloading it as a PDF. Visit NAP.edu/10766 to get more information about this ...
Hosted on MSN

Whooping cough is making a comeback, but the vaccine provides powerful protection

Whooping cough, a bacterial infection that can be especially dangerous for babies and young children, is on the rise. Already in 2025 the U.S. has recorded 8,485 cases. That's compared with 4,266 ...